Nuropod Auricular Vagal Neuromodulation Device: Clinical Evidence Guide Released

Oct 14, 2026

As auricular vagus nerve stimulation becomes a wider area of clinical research, Parasym releases a guide to the peer-reviewed clinical evidence behind the proprietary AVNT™ technology used in Nuropod.

Sacramento, United States, October 14, 2026 /PressCable/ -- In a recently released guide, Parasym draws attention to the clinical research supporting the auricular vagal neuromodulation technology behind Nuropod, its wearable vagus nerve stimulation device. Developed following more than a decade of research and development, the device uses the company’s proprietary AVNT™ waveform at the tragus, applying a noninvasive approach that has been evaluated across a growing program of clinical studies.

More information about the research is available at https://nuropod.com/pages/scientific-evidence

The latest guide from Parasym comes as transcutaneous auricular vagus nerve stimulation is being investigated across an increasingly broad range of research settings. A 2024 scoping review published on PubMed identified 109 studies covering 21 clinical populations, while also finding considerable variation in stimulation methods and study design. That variation makes the technology and protocol used in individual studies an important part of interpreting the resulting evidence.

Parasym’s research program, therefore, centers specifically on its own AVNT method. According to the company, more than 60 studies using its neuromodulation technology have been completed following over $10 million in research and development, with more than 150 research institutions involved in its wider scientific program.

The technology targets the auricular branch of the vagus nerve at the tragus, where the nerve reaches the skin of the outer ear. Gentle electrical pulses are delivered through the earpiece using Parasym’s proprietary waveform, providing a noninvasive route for vagus nerve stimulation without surgery.

The vagus nerve carries signals between the brain and organs including the heart, lungs and gut and contributes to functions associated with stress, rest and recovery. Parasym Head of Research Dr. Elisabetta Burchi says the company’s work is focused on using that existing biological pathway rather than overriding it. “Nuropod doesn't override our biology, but leverages a natural system that we already have to mitigate homeostatic imbalances often caused by our unhealthy lifestyles and the pace of our over-demanding society.”

As per the guide, research using Parasym’s technology has examined both autonomic and cognitive measures. In clinical studies, heart rate variability increased by an average of 18%, while attention improved by an average of 11%.

The latest research has also informed how Nuropod is designed for everyday use, with most users wearing the device for around 30 minutes once or twice daily while carrying out ordinary activities, extending the noninvasive approach beyond laboratory and clinical research settings.

Access to the full guide about Parasym’s clinical research and Nuropod is available at https://nuropod.com/pages/scientific-evidence

Disclaimer: Research referenced in this article was conducted using Parasym’s neuromodulation technology under research conditions. Findings relate to specific study populations and should not be interpreted as guaranteed individual outcomes. Nuropod is classified by the FDA as a non-significant risk device and is not intended to diagnose, treat, cure, or prevent any disease.

Contact Info:
Name: PR Team
Email: Send Email
Organization: Nuropod by Parasym
Address: 2108 N Street, Sacramento, California 95816, United States
Website: https://nuropod.com/

Source: PressCable

Release ID: 89206183

Should any problems, inaccuracies, or doubts arise from the content contained within this press release, we kindly request that you inform us immediately by contacting [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our dedicated team will promptly address your concerns within 8 hours, taking necessary steps to rectify identified issues or assist with the removal process. Providing accurate and dependable information is at the core of our commitment to our readers.

More News

article.head.headline
Nov 13, 2026
Sarah Paulson: I don’t put anything in my face

All's Fair star Sarah Paulson insists she's ageing naturally.

article.head.headline
Nov 13, 2026
Stephen Graham did 'quite a lot of training' for Nocturne

Stephen Graham has revealed how he prepared for his role in Nocturne.

article.head.headline
Nov 13, 2026
Julianne Moore feels proud of Still Alice

Julianne Moore has reflected on the impact of Still Alice, the 2014 drama movie.

article.head.headline
Nov 13, 2026
Amanda Seyfried wants Hollywood to be 'brave'

Amanda Seyfried wants to see Hollywood continue to take risks.

article.head.headline
Nov 13, 2026
Pop star Avril Lavigne welcomes a baby girl

Avril Lavigne has announced the arrival of her baby girl via a social media post.

article.head.headline
Nov 13, 2026
Halle Bailey's son is 'musically inclined and intelligent'

Halle Bailey has revealed that her two-year-old son is already musical.

article.head.headline
Nov 13, 2026
Amanda Seyfried has 'low expectations', but why?

Hollywood star Amanda Seyfried has discussed her approach to awards season.

article.head.headline
Nov 13, 2026
Infected by the beat: Cascada is still hot on the dance floor, The Court December show sold-out

Perth fans heading to The Court can expect other nostalgic bangers such as Miracle and Bad Boy as well as newly released singles.

article.head.headline
Nov 13, 2026
What To Watch TV Reviews: Mark Of A Murderer, Rivals, 2.6 Seconds, Percy Jackson and Yellowjackets

Mark Of A Murderer, the second season of Rivals, 2.6 Seconds: Death In The Outback, the third Percy Jackson and Yellowjackets’ final season: here’s what we’re watching this week.

article.head.headline
Nov 13, 2026
Avril Lavigne welcomes 'princess' first child

Rock singer Avril Lavigne has announced she has given birth to a baby girl in an Instagram post.

article.head.headline
Nov 13, 2026
Ocean Colour Scene ready to record first new album in more than a decade

Ocean Colour Scene guitarist Steve Cradock says the band are keen to make a new album, their first since 2013's Painting.

article.head.headline
Nov 13, 2026
'I find it beneath the country': Joe Biden is appalled by Donald Trump's White House renovations

Former US President Joe Biden has described his successor Donald Trump's changes to the White House as "disturbing".


YOUR NEWS, OUR NETWORK.

Do you have Great News you want to tell the world?

Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.

E-Stardom

E-Stardom is the exclusive online news network for breaking entertainment news. We bring to you the premium coverage and fashion tips to your favorite celebrity style. Get your daily celebrity news fix only here in E-Stardom.